Literature DB >> 35882999

AKTing on XPO1 inhibition in AML.

Stefanie Göllner1, Carsten Müller-Tidow2,3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35882999     DOI: 10.1038/s43018-022-00395-w

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


× No keyword cloud information.
  2 in total

1.  Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.

Authors:  Aya Shiba-Ishii; Ted W Johnson; Ibiayi Dagogo-Jack; Mari Mino-Kenudson; Theodore R Johnson; Ping Wei; Scott L Weinrich; Michele A McTigue; Makeba A Walcott; Linh Nguyen-Phuong; Kristin Dionne; Adam Acker; Lesli A Kiedrowski; Andrew Do; Jennifer L Peterson; Jaimie L Barth; Beow Y Yeap; Justin F Gainor; Jessica J Lin; Satoshi Yoda; Aaron N Hata
Journal:  Nat Cancer       Date:  2022-06-20

Review 2.  MicroRNA: Crucial modulator in purinergic signalling involved diseases.

Authors:  Jing Guo; Peng Yang; Yi-Fan Li; Jin-Fan Tang; Zhao-Xuan He; Shu-Guang Yu; Hai-Yan Yin
Journal:  Purinergic Signal       Date:  2022-02-02       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.